What are we worth guys?This publication from 2017 would have us...

What are we worth guys?

This publication from 2017 would have us over-valued (pg 34) https://www2.asx.com.au/content/dam/asx/documents/listings/AusBiotech-Guide-to-Life-Sciences-Investing-web-version.pdf

I had a look through the article from stock head titled "Clinical Trials Tracker: The tests ASX healthcare companies have upcoming in 2021" and from what I could gather NEU looks to be the closest like for like I could find - although still very very different - but perhaps useful for some basis of comparison... NEU have a market cap of 186m, so over 3x ours, but are also considerably ahead of us in the development of their drug - they are beginning several Ph2 and have some Ph3 results coming. There are many other key differences, which you can see for yourself here: https://hotcopper.com.au/threads/ann-investor-presentation-15-june-2021.6110345/ - but one other noteworthy difference is that NSB would have a much higher TAM (although I dont know the exact figure of a TAM for NEU - they are targeting more niche conditions). A quick browse on their thread and this post also was useful to get some discussion going: https://hotcopper.com.au/threads/valuations.6106726/page-6?get_post=true
*I dont own any NEU - this is for comparison only - and is a very high level one at that

We may not need a catalyst for a price spike, we will hopefully gradually edge up as we commence and then carry out Ph1 trials. Hopefully this time next year we have an answer whether this works in Glaucoma patients or not!

GLTAH